BIOCRYST PHARMACEUTICALS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BIOCRYST PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $6.21M, a 81.58% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $18.37M, a 1394.39% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.57M, a 14.98% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $3.42M, a 1195.83% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $7.88M, a 245.57% increase from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $2.28M, a 62.71% decline from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $6.11M, a 48.62% decline from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $11.90M, a 13.42% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $6.21M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $18.37M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $7.88M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $1.57M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $3.42M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $1.23M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $2.28M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.36M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $264.00K 10-Q · filed 2025-11-04 | |
| 2024-03-31 | $552.00K 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $6.11M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $456.00K 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $1.75M 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $3.50M 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $11.90M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $1.90M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $145.00K 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $5.85M 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $13.74M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $3.54M 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $4.57M 10-Q · filed 2022-11-04 | |
| 2021-03-31 | $2.18M 10-Q · filed 2022-11-04 | |
| 2020-12-31 | $1.81M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $366.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $532.00K 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $266.00K 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $835.00K 10-K · filed 2022-02-28 | |
| 2019-06-30 | $414.00K 10-Q · filed 2020-11-06 | |
| 2019-03-31 | $343.00K 10-Q · filed 2020-11-06 | |
| 2018-12-31 | $2.50M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $595.00K 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $468.00K 10-Q · filed 2019-11-08 | |
| 2018-03-31 | $81.00K 10-Q · filed 2019-11-08 | |
| 2017-12-31 | $1.24M 10-K · filed 2020-03-13 | |
| 2016-12-31 | -$12.00K 10-K · filed 2019-03-14 | |
| 2015-12-31 | $5.12M 10-K · filed 2018-03-12 | |
| 2014-12-31 | $5.00M 10-K · filed 2017-02-27 | |
| 2013-12-31 | $1.33M 10-K · filed 2016-02-26 | |
| 2012-12-31 | $539.00K 10-K · filed 2015-03-02 | |
| 2011-12-31 | $278.00K 10-K · filed 2014-03-10 | |
| 2010-12-31 | $552.00K 10-K · filed 2013-03-11 | |
| 2009-12-31 | $2.12M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |